VitalMedix Inc., founded in 2005, is a biopharmaceutical research company focused on developing treatments to sustain cellular function and protect cells during and after hemorrhagic shock. Their core mission is to enhance human survival rates and organ protection in critical conditions involving severe blood loss. The company's flagship product, Tamiasyn, aims to enable the human body to endure significant blood loss for extended periods and mitigate organ damage during resuscitation. VitalMedix primarily targets the healthcare market, particularly emergency medicine and trauma care.

Notable figures affiliated with VitalMedix include its founding team of scientists and medical researchers with expertise in cellular biology and emergency medicine. The company has garnered attention from investors interested in groundbreaking medical technologies. Key achievements include the development and preliminary testing of Tamiasyn, which has shown promise in preclinical trials. VitalMedix's work has the potential to significantly impact trauma care practices, offering new hope for patients experiencing severe hemorrhagic shock.